DATANG POWER (00991) completed a cumulative grid-connected electricity of approximately 624.091 billion kilowatt-hours in the first quarter, an increase of about 3.46% year-on-year.
Datang Power Generation (00991) announced that as of March 31, 2026, the company and its subsidiaries have collectively completed a total of approximately 624.091 billion kilowatt-hours of electricity generation, representing a year-on-year increase of about 3.46%.
DATANG POWER (00991) announced that as of March 31, 2026, the company and its subsidiaries have cumulatively completed a grid-connected power generation of approximately 624.091 billion kilowatt-hours, an increase of about 3.46% compared to the previous year.
The main reasons for the change in grid-connected power generation in the first quarter of 2026 were: an increase in overall electricity consumption, a year-on-year growth in installed capacity of thermal power plants, favorable water conditions for hydropower units in the Chongqing and Yunnan regions where the company operates, among other factors. As a result, the grid-connected power generation from thermal and hydropower plants saw a significant increase year-on-year, effectively boosting the overall electricity output of the company.
As of March 31, 2026, the average grid-connected electricity price for the company was approximately RMB 438.78 per megawatt-hour (including tax), a decrease of about 4.8% compared to the previous year. In the first quarter of 2026, the company's market trading electricity volume was approximately 510.54 billion kilowatt-hours, accounting for about 81.81% of the total.
As of March 31, 2026, the company's total installed capacity was 85.8 gigawatts, with thermal coal power plants accounting for 48.7 gigawatts, thermal gas power plants 9479.38 megawatts, hydropower 9204.73 megawatts, wind power 11.2 gigawatts, and photovoltaic power 7185.375 megawatts.
Related Articles

GF SEC(01776): "23 GF04" interest payment redemption and delisting, "23 GF05" interest payment

HANXBIO-B (03378) spent 98.85 million Hong Kong dollars to repurchase 31,200 shares on April 22nd.

SINOPHARM(01099): The net profit attributable to shareholders of China National Medicines Corporation(600511.SH) in the first quarter was 474 million yuan, a year-on-year increase of 3.32%.
GF SEC(01776): "23 GF04" interest payment redemption and delisting, "23 GF05" interest payment

HANXBIO-B (03378) spent 98.85 million Hong Kong dollars to repurchase 31,200 shares on April 22nd.

SINOPHARM(01099): The net profit attributable to shareholders of China National Medicines Corporation(600511.SH) in the first quarter was 474 million yuan, a year-on-year increase of 3.32%.

RECOMMEND

DeepSeek’s $10 Billion Valuation Financing Rumor And Four Layers Of Logical Judgment
21/04/2026

48 Hours Witness AI’s New Battlefield: Alibaba Joins, Tencent Open Sources, Manycore Tech Lists — Has The World Model Reached Its ChatGPT Moment?
21/04/2026

Public Fund Giants Reverse Course With Heavy Hong Kong IPO Cornerstone Allocations Exceeding HK$2.2 Billion Year‑To‑Date
21/04/2026


